手术治疗前的预后营养指数可作为上尿路尿路上皮癌患者的预后生物标志物：一项系统评价和荟萃分析。
Prognostic nutritional index before surgical treatment may serve as a prognostic biomarker for patients with upper tract urothelial carcinoma: A systematic review and meta-analysis.
作者信息
Meng Chunyang, Gan Lijian, Li Kangsen, Yi Fulin, Peng Lei, Li Jinze, Li Yunxiang
机构信息
Department of Urology, The Affiliated Nanchong Central Hospital of North Sichuan Medical College (University), Nanchong, China.
Department of Anesthesiology, North Sichuan Medical College (University), Nanchong, China.
出版信息
Front Nutr. 2022 Sep 23;9:972034. doi: 10.3389/fnut.2022.972034. eCollection 2022.
OBJECTIVE
This meta-analysis aims to assess whether the prognostic nutritional index (PNI) score before treatment can be an independent biomarker of the prognosis of patients with upper tract urothelial carcinoma (UTUC).
MATERIALS AND METHODS
We systematically search PubMed, Embase, Scopus database, and Cochrane Library, and the search time is up to April 2021. Use STATA 16.0 software for data processing and statistical analysis.
RESULTS
Six studies, including seven cohorts, were eventually included in our meta-analysis. The meta-analysis results showed that low PNI scores are associated with worse OS (HR: 1.92; 95% CI 1.60 to 2.30; < 0.01), DFS/RFS/PFS (HR: 1.57; 95% CI 1.33 to 1.85; < 0.01), and CSS/DSS (HR: 1.79; 95% CI 1.49 to 2.16; < 0.01), which supported the PNI score as an independent prognostic biomarker for survival outcomes. The subgroup analysis and Begg's test showed that the results were stable.
CONCLUSION
Based on current evidence, this meta-analysis proves that the PNI score of UTUC patients before treatment is an independent prognostic biomarker. It performs well on OS, DFS/RFS/PFS, and CSS/DSS. This conclusion needs to be verified by a prospective cohort study with larger sample size and a more rigorous design.
SYSTEMATIC REVIEW REGISTRATION
[https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022338503], identifier [CRD42022338503].
目的
本荟萃分析旨在评估治疗前的预后营养指数（PNI）评分是否可作为上尿路尿路上皮癌（UTUC）患者预后的独立生物标志物。
材料与方法
我们系统检索了PubMed、Embase、Scopus数据库和Cochrane图书馆，检索时间截至2021年4月。使用STATA 16.0软件进行数据处理和统计分析。
结果
最终有六项研究（包括七个队列）纳入我们的荟萃分析。荟萃分析结果显示，低PNI评分与较差的总生存期（HR：1.92；95%CI 1.60至2.30；P<0.01）、无病生存期/疾病复发生存期/无进展生存期（HR：1.57；95%CI 1.33至1.85；P<0.01）以及癌症特异生存期/疾病特异生存期（HR：1.79；95%CI 1.49至2.16；P<0.01）相关，这支持了PNI评分作为生存结局的独立预后生物标志物。亚组分析和Begg检验表明结果稳定。
结论
基于现有证据，本荟萃分析证明UTUC患者治疗前的PNI评分是独立的预后生物标志物。它在总生存期、无病生存期/疾病复发生存期/无进展生存期以及癌症特异生存期/疾病特异生存期方面表现良好。这一结论需要通过样本量更大、设计更严谨的前瞻性队列研究来验证。
系统评价注册
[https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022338503]，标识符[CRD42022338503]。
Zotero 插件